Paloma Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Paloma Partners’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-41,200	Closed	-$1.44M	–	1597
2020 Q3	$1.44M	Buy	+41,200	New	+$1.81M	0.04%	524
2019 Q2	–	Sell	-14,765	Closed	-$996K	–	1688
2019 Q1	$996K	Buy	+14,765	New	+$860K	0.02%	732
2018 Q3	–	Sell	-7,375	Closed	-$621K	–	1502
2018 Q2	$621K	Sell	7,375 -3,825	-34%	-$334K	0.01%	928
2018 Q1	$916K	Buy	+11,200	New	+$866K	0.01%	1036
2017 Q4	–	Sell	-20,574	Closed	-$1.37M	–	1841
2017 Q3	$1.37M	Buy	+20,574	New	+$1.24M	0.02%	976
2017 Q2	–	Sell	-20,977	Closed	-$1.23M	–	2130
2017 Q1	$1.23M	Buy	+20,977	New	+$1.01M	0.01%	1111
2015 Q3	–	Sell	-28,750	Closed	-$3.19M	–	1582
2015 Q2	$3.19M	Buy	+28,750	New	+$3.1M	0.06%	290

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Paloma Partners's AGIO Position: Q4 2020 in Review

Paloma Partners sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 41,200 shares — an estimated $1.44M sold.

Paloma Partners first reported a position in AGIO in Q2 2015 and held it in 7 quarters. The position peaked at $3.19M in Q2 2015. 201 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

Paloma Partners reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 41,200 Agios Pharmaceuticals shares in Q4 2020, an estimated $1.44M.
Paloma Partners first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Paloma Partners's Agios Pharmaceuticals position peaked at $3.19M in Q2 2015.
201 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.